TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
Brief Summary: This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS. The study will enroll approximately 435 subjects at up to 60 sites in the United States and Canada.


Options:
A: Arm Label: FTY720 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: FTY720 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720 0.5 mg, FTY720 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Laquinimod 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod 0.6 mg, Laquinimod 1.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Laquinimod 0.6 mg
C: Arm Label: Double-blind Natalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Arm Label: Double-blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-label Natalizumab; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Intervention Type: DRUG; Name: Natalizumab (BG00002); Assigned to Arm(s): Double-blind Natalizumab 300 mg, Open-label Natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintaining Abstinence in Chronic Cigarette Smokers
Brief Summary: The purpose of this study is to evaluate the extended pharmacological and psychological treatment for chronic cigarette smokers.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
C: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/Low Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/Low Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/High Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/High Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Intervention Type: DRUG; Name: Bupropion and NRT; Assigned to Arm(s): Brief Treatment, Extended Bupropion/High Contact, Extended Bupropion/Low Contact, Extended Placebo/High Contact, Extended Placebo/Low Contact
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintaining Abstinence in Chronic Cigarette Smokers
Brief Summary: The purpose of this study is to evaluate the extended pharmacological and psychological treatment for chronic cigarette smokers.


Options:
A: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/Low Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/Low Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/High Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/High Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Intervention Type: DRUG; Name: Bupropion and NRT; Assigned to Arm(s): Brief Treatment, Extended Bupropion/High Contact, Extended Bupropion/Low Contact, Extended Placebo/High Contact, Extended Placebo/Low Contact
B: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintaining Abstinence in Chronic Cigarette Smokers
Brief Summary: The purpose of this study is to evaluate the extended pharmacological and psychological treatment for chronic cigarette smokers.


Options:
A: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
B: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/Low Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/Low Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/High Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/High Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Intervention Type: DRUG; Name: Bupropion and NRT; Assigned to Arm(s): Brief Treatment, Extended Bupropion/High Contact, Extended Bupropion/Low Contact, Extended Placebo/High Contact, Extended Placebo/Low Contact
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion (Wellbutrin) | Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density.
Brief Summary: The purpose of this trial is to study:

* Effects of arzoxifene on bone fractures and bone mass.
* Effects of arzoxifene on getting breast cancer.
* Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke.
* Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health.
* Effects of arzoxifene on the uterus.
* The safety of arzoxifene and any side effects.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Arzoxifene | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arzoxifene; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tibolone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tibolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo
Brief Summary: The purpose of the protocol is to evaluate the efficacy and safety of olanzapine compared with placebo in patients with Borderline Personality Disorder (BPD).


Options:
A: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
B: Arm Label: suicide attempt patient who will receive sanitory supervision; Type: OTHER; Interventions: Other: suicide attempt patient using PEPS Program | Arm Label: Suicide attempt patient who will participate to PEPS Program; Type: EXPERIMENTAL; Interventions: Other: suicide attempt patient using PEPS Program | Intervention Type: OTHER; Name: suicide attempt patient using PEPS Program; Assigned to Arm(s): Suicide attempt patient who will participate to PEPS Program, suicide attempt patient who will receive sanitory supervision
C: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
D: Arm Label: therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioural therapy | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioural therapy; Assigned to Arm(s): therapy | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo
Brief Summary: The purpose of the protocol is to evaluate the efficacy and safety of olanzapine compared with placebo in patients with Borderline Personality Disorder (BPD).


Options:
A: Arm Label: I ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ziprasidone | Arm Label: II placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): I ziprasidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): II placebo
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
C: Arm Label: Follow up; Type: EXPERIMENTAL; Interventions: Behavioral: Follow up | Arm Label: Usual Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Follow up; Assigned to Arm(s): Follow up
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group 1, Group 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Crossover, Open Label Dose Finding Study to Compare the Safety, Efficacy and PK/PD Relationship of Multiple Doses of SOM230 and Sandostatin in Acromegalic Patients
Brief Summary: 5 month study comparing SOM230 s.c. and Sandostatin s.c. in acromegalic patients.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide Implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sandostatin LAR Depot | Intervention Type: DRUG; Name: Octreotide Implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sandostatin LAR Depot; Assigned to Arm(s): 2
B: Arm Label: Sandostatin s.c. (Octreotide); Type: EXPERIMENTAL; Interventions: Drug: Pasireotide (SOM230), Octreotide (Sandostatin) | Arm Label: Pasireotide (SOM230); Type: EXPERIMENTAL; Interventions: Drug: Pasireotide (SOM230), Octreotide (Sandostatin) | Intervention Type: DRUG; Name: Pasireotide (SOM230), Octreotide (Sandostatin); Assigned to Arm(s): Pasireotide (SOM230), Sandostatin s.c. (Octreotide)
C: Arm Label: Pasireotide LAR 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Pasireotide LAR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Control arm (octreotide or lanreotide); Type: ACTIVE_COMPARATOR; Interventions: Drug: octreotide LAR 30mg, Drug: lanreotide ATG 120mg | Intervention Type: DRUG; Name: Pasireotide; Assigned to Arm(s): Pasireotide LAR 40 mg, Pasireotide LAR 60 mg | Intervention Type: DRUG; Name: octreotide LAR 30mg; Assigned to Arm(s): Control arm (octreotide or lanreotide) | Intervention Type: DRUG; Name: lanreotide ATG 120mg; Assigned to Arm(s): Control arm (octreotide or lanreotide)
D: Arm Label: Pasireotide LAR; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide | Intervention Type: DRUG; Name: Pasireotide; Assigned to Arm(s): Pasireotide LAR | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Octreotide LAR

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist
Brief Summary: Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses. Recent preclinical and clinical studies suggest that the glutamatergic system is involved in the mechanism of action of antidepressants.

This study examines whether ketamine can cause a rapid-next day antidepressant effect in patients with Major Depressive Disorder.

This study was designed to address the questions:

Does the NMDA antagonist ketamine produce rapid antidepressant effects in patients with treatment-resistant major depression? What are the neurobiological correlates of antidepressant response (examining multi-modal MRI, MEG, polysomnography and serum markers) Patients, ages 18 to 65 years with treatment-resistant major (unipolar) depression will in a double-blind crossover study receive either intravenous ketamine or saline solution.


Options:
A: Arm Label: Ketamine, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ketamine, Drug: Placebo | Arm Label: Placebo, Then Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine, Drug: Placebo | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine, Then Placebo, Placebo, Then Ketamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ketamine, Then Placebo, Placebo, Then Ketamine
B: Arm Label: AZD6765 (150 mg) / Placebo; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: Placebo / AZD6765 (150 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to AZD6765 | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 (150 mg) / Placebo | Intervention Type: DRUG; Name: Placebo to AZD6765; Assigned to Arm(s): Placebo / AZD6765 (150 mg)
C: Arm Label: Ketamine Interventional Arm; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Methohexital Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methohexital | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine Interventional Arm | Intervention Type: DRUG; Name: Methohexital; Assigned to Arm(s): Methohexital Control Arm
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease
Brief Summary: RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation. It is not yet known whether immunosuppressive treatment regimens are more effective with or without mycophenolate mofetil in treating chronic graft-versus-host disease.

PURPOSE: This randomized phase III trial is studying whether the addition of mycophenolate mofetil improves the efficacy of immunosuppressive treatment regimens in patients with newly diagnosed chronic graft-versus-host disease.


Options:
A: Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Methoxsalen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Extracorporeal Photopheresis; Assigned to Arm(s): N/A
C: Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease
Brief Summary: RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation. It is not yet known whether immunosuppressive treatment regimens are more effective with or without mycophenolate mofetil in treating chronic graft-versus-host disease.

PURPOSE: This randomized phase III trial is studying whether the addition of mycophenolate mofetil improves the efficacy of immunosuppressive treatment regimens in patients with newly diagnosed chronic graft-versus-host disease.


Options:
A: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A
B: Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: N/A
D: Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1
Brief Summary: The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1
B: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): N/A
D: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B